论文部分内容阅读
我院研制的“北新一号”抗结核复方,经试管内抑菌试验,表明对结核杆菌有较强的抑制作用;经豚鼠实验性结核病疗效观察,有明显疗效。自1979年4月开始,我院将“北新一号”应用于临床实践,治疗结核性窦道患者共70例,治愈率为91.4％,总有效率达95.7％。本文略作介绍。一、临床资料 (一)患者概况(见表1) 患者年龄最大为69岁。发病最短为5个月,最长为28年。 (二)诊断依据 1.患有周围淋巴结核、胸壁结核、腹壁结核等病症,结核破溃,在伤口可见干酪样变或有钙化结石排出。 2.病理切片证实为结核性;浓液涂片查出抗酸杆菌;患骨结核者X线检查可见骨质破坏。
Our hospital developed “North New One” anti-TB compound, by in vitro antibacterial test, that Mycobacterium tuberculosis has a strong inhibitory effect; Observed by guinea pig experimental tuberculosis efficacy, significant effect. Since April 1979, our hospital has applied “Beixin No.1” to clinical practice. A total of 70 patients with tuberculous sinuses were treated. The cure rate was 91.4% and the total effective rate was 95.7%. This article is a brief introduction. First, the clinical data (A) the patient profile (see Table 1) The oldest patient was 69 years old. The shortest onset is 5 months, the longest is 28 years. (B) of the diagnosis based on 1 with peripheral lymph nodes, chest wall tuberculosis, abdominal wall tuberculosis and other diseases, tuberculosis ulceration, visible in the wound caseous calcification or calcification of stone discharge. 2. Pathological confirmed tuberculous; smear acid-fast bacilli; X-ray examination of bone tuberculosis can be seen bone destruction.